title: Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
abstract: The case of a patient with a uterine leiomyosarcoma (LMS) that rapidly recurred in the pelvis following primary surgery is reported. The tumor was refractory to conventional multiagent chemotherapy that included intravenously administered etoposide (VP-16). Etoposide was then administered orally in a prolonged schedule; this resulted in a sustained partial response with palliation of symptoms. Thus, prolonged oral administration of etoposide may have antitumor activity against LMS despite that tumor's resistance to short-term infusion schedules of etoposide.
authors.affiliation: Rajvithi Hospital, Bangkok, Thailand.
authors.forename: P
authors.initials: P
authors.lastname: Chantarawiroj
authors.forename: D
authors.initials: D
authors.lastname: Tresukosol
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: E G
authors.initials: EG
authors.lastname: Silva
authors.forename: J T
authors.initials: JT
authors.lastname: Wharton
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007890:Leiomyosarcoma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D005047:Etoposide